Stay updated with breaking news from Lxrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) CFO Jeffrey L. Wade bought 12,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was purchased at an average cost of $2.33 per share, for a total transaction of $27,960.00. Following the completion of the transaction, the chief financial officer now owns […]
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) traded down 4.3% on Friday . The company traded as low as $2.90 and last traded at $2.90. 806,027 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 1,143,010 shares. The stock had previously closed at $3.03. Analyst Upgrades […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) Director International S.C.A. Artal acquired 27,775,050 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was acquired at an average cost of $2.60 per share, with a total value of $72,215,130.00. Following the completion of the purchase, the director now owns 78,634,381 […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) was up 10.2% on Wednesday . The stock traded as high as $2.95 and last traded at $2.93. Approximately 3,253,692 shares were traded during trading, an increase of 195% from the average daily volume of 1,103,374 shares. The stock had previously closed at $2.66. Analyst Upgrades and Downgrades […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) had its target price upped by equities researchers at Citigroup from $6.00 to $8.00 in a note issued to investors on Wednesday, The Fly reports. Citigroup’s price objective would suggest a potential upside of 195.20% from the stock’s current price. A number of other brokerages also recently issued reports […]